Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL)

72 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 as of Q3 2025.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,484,049 shares of 19,139,684 outstanding shares and own 50% of the company stock.
Largest 10 shareholders include ARCH Venture Management, LLC (2,759,072 shares), MWG Management Ltd. (1,008,116 shares), Foresite Capital Management IV, LLC (800,399 shares), VANGUARD GROUP INC (779,004 shares), Orland Properties Ltd (754,698 shares), Almitas Capital LLC (577,807 shares), Foresite Capital Management V, LLC (477,078 shares), venBio Partners LLC (473,479 shares), CITADEL ADVISORS LLC (339,491 shares), and Alphabet Inc. (293,256 shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.